Shares of Spyre Therapeutics (SYRE) have gained 14.7% over the past four weeks to close the last trading session at $14.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $53.50 indicates a potential upside of 258.3%.The mean estimate comprises 10 short-term price targets with a standard deviation of $16.36. While the lowest estimate of $21 indicates a 40.7% increase from the c ...

Group 1 - Dream Finders Homes Inc. (DFH) has surpassed resistance at the 50-day moving average, indicating a potential short-term bullish trend [1] - DFH has moved 8.6% higher over the last four weeks, suggesting it may be on the verge of another rally [2] - The company is currently rated as a Zacks Rank 2 (Buy), reflecting positive investor sentiment [2] Group 2 - There have been two positive earnings estimate revisions for DFH, with none being lowered for the current fiscal year, indicating strong earnings momentum [2] - The consensus earnings estimate for DFH has also increased, further strengthening the bullish outlook [2][3] - The combination of positive earnings revisions and key technical levels suggests that DFH could see more gains in the near future [3]

Sezzle Inc. (SEZL) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings e ...

Core Viewpoint - OppFi Inc. (OPFI) is showing a significantly improving earnings outlook, making it an attractive option for investors as analysts continue to raise their earnings estimates for the company [1][2]. Earnings Estimate Revisions - Analysts' optimism regarding OppFi's earnings prospects is leading to higher estimates, which is expected to positively impact the stock price [2]. - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. - The consensus estimate for the current quarter has increased by 7.27% over the last 30 days, with the current-quarter estimate at $0.30 per share, reflecting a +3.45% change year-over-year [7]. - For the full year, OppFi is projected to earn $1.16 per share, representing a +22.11% year-over-year change, with a 15.89% increase in consensus estimates over the past month [8][9]. Zacks Rank and Investment Potential - OppFi currently holds a Zacks Rank 1 (Strong Buy) due to favorable estimate revisions, indicating strong potential for outperformance compared to the S&P 500 [10]. - The stock has appreciated by 37.4% over the past four weeks, suggesting that further upside may still be possible, making it a candidate for portfolio addition [11].

Investors might want to bet on GSK (GSK) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors ...

Clover Health Investments, Corp. (CLOV) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Core Viewpoint - DexCom (DXCM) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for DexCom reflects an improvement in its underlying business, suggesting that investor sentiment may drive the stock price higher [4]. - DexCom is projected to earn $2.02 per share for the fiscal year ending December 2025, representing a year-over-year increase of 23.2% [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - DexCom's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Avadel (AVDL) closed the last trading session at $9.39, gaining 22.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.80 indicates a 100.2% upside potential.The average comprises 10 short-term price targets ranging from a low of $12 to a high of $27, with a standard deviation of $4.59. While the lowest estimate indicates an increase of 27.8% from the current price level, the mo ...

Shares of Great Lakes Dredge & Dock (GLDD) have gained 20.5% over the past four weeks to close the last trading session at $10.70, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.33 indicates a potential upside of 33.9%.The average comprises three short-term price targets ranging from a low of $14 to a high of $15, with a standard deviation of $0.58. While the lowest estimat ...

Group 1 - CryoPort, Inc. (CYRX) shares have increased by 22.5% in the past four weeks, closing at $7.07, with a mean price target of $10.94 indicating a potential upside of 54.7% [1] - The average price targets from analysts range from a low of $6.50 to a high of $15, with a standard deviation of $3.05, suggesting variability in estimates [2] - Analysts are optimistic about CYRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for CYRX's current year earnings has increased by 23.2% over the past month, with four estimates revised upward and no negative revisions [12] - CYRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets may not be entirely reliable, the direction they imply can serve as a useful guide for potential price movements [10][13]